Hydroxamic Acid Derivatives of Mycophenolic Acid Inhibit Histone Deacetylase at the Cellular Level
作者:Daniela I. BATOVSKA、Dong Hoon KIM、Shinya MITSUHASHI、Yoon Sun CHO、Ho Jeong KWON、Makoto UBUKATA
DOI:10.1271/bbb.80303
日期:2008.10.23
Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARγ agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC50 values of 1, 0.9 and 0.5 μM, and cell proliferation at concentrations of 2, 1.5 and 1 μM, respectively.
麦克芬酸(MPA,1)是一种IMP脱氢酶(IMPDH)抑制剂和潜在的PPARγ激动剂,作为一种有效的免疫抑制剂用于临床移植,并且最近已在晚期多发性骨髓瘤患者中进入临床试验。另一方面,亚丁酸(SAHA)是一种非特异性组蛋白去乙酰化酶(HDAC)抑制剂,已被批准用于治疗皮肤T细胞淋巴瘤。MPA似乎具有一个帽结构、一个链接器和一个弱金属结合位点,作为HDAC的潜在抑制剂。因此,设计并合成了具有有效金属结合位点的麦克芬酸氢氧酸衍生物:麦克芬酸氢氧酸(MPHA,2)、7-O-乙酰麦克芬酸(7-O-Ac MPHA,3)和7-O-月桂酰麦克芬酸氢氧酸(7-O-L MPHA,4)。所有这些化合物均抑制组蛋白去乙酰化酶,其IC50值分别为1、0.9和0.5μM,细胞增殖抑制浓度为2、1.5和1μM。